Injection Molding Materials
Injection Molding Materials market is segmented by region (country), players, by Type and by Appl ... Read More
1 Study Coverage 1.1 Immuno-oncology Drugs Product Introduction 1.2 Global Immuno-oncology Drugs Outlook 2017 VS 2022 VS 2028 1.2.1 Global Immuno-oncology Drugs Sales in US$ Million for the Year 2017-2028 1.2.2 Global Immuno-oncology Drugs Sales in Volume for the Year 2017-2028 1.3 United States Immuno-oncology Drugs Outlook 2017 VS 2022 VS 2028 1.3.1 United States Immuno-oncology Drugs Sales in US$ Million for the Year 2017-2028 1.3.2 United States Immuno-oncology Drugs Sales in Volume for the Year 2017-2028 1.4 Immuno-oncology Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4.1 The Market Share of United States Immuno-oncology Drugs in Global, 2017 VS 2022 VS 2028 1.4.2 The Growth Rate of Immuno-oncology Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.5 Immuno-oncology Drugs Market Dynamics 1.5.1 Immuno-oncology Drugs Industry Trends 1.5.2 Immuno-oncology Drugs Market Drivers 1.5.3 Immuno-oncology Drugs Market Challenges 1.5.4 Immuno-oncology Drugs Market Restraints 1.6 Study Objectives 1.7 Years Considered 2 Market by Type 2.1 Immuno-oncology Drugs Market Segment by Type 2.1.1 Immune Checkpoint Inhibitors 2.1.2 Immune System Modulators 2.1.3 Cancer Vaccines 2.1.4 Oncolytic Virus 2.1.5 Others 2.2 Global Immuno-oncology Drugs Market Size by Type 2.2.1 Global Immuno-oncology Drugs Sales in Value, by Type (2017, 2022 & 2028) 2.2.2 Global Immuno-oncology Drugs Sales in Volume, by Type (2017, 2022 & 2028) 2.2.3 Global Immuno-oncology Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028) 2.3 United States Immuno-oncology Drugs Market Size by Type 2.3.1 United States Immuno-oncology Drugs Sales in Value, by Type (2017, 2022 & 2028) 2.3.2 United States Immuno-oncology Drugs Sales in Volume, by Type (2017, 2022 & 2028) 2.3.3 United States Immuno-oncology Drugs Average Selling Price (ASP) by Type (2017, 2022 & 2028) 3 Market by Application 3.1 Immuno-oncology Drugs Market Segment by Application 3.1.1 Hospitals 3.1.2 Clinics 3.1.3 Ambulatory Surgical Centers 3.2 Global Immuno-oncology Drugs Market Size by Application 3.2.1 Global Immuno-oncology Drugs Sales in Value, by Application (2017, 2022 & 2028) 3.2.2 Global Immuno-oncology Drugs Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 Global Immuno-oncology Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028) 3.3 United States Immuno-oncology Drugs Market Size by Application 3.3.1 United States Immuno-oncology Drugs Sales in Value, by Application (2017, 2022 & 2028) 3.3.2 United States Immuno-oncology Drugs Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 United States Immuno-oncology Drugs Average Selling Price (ASP) by Application (2017, 2022 & 2028) 4 Global Immuno-oncology Drugs Competitor Landscape by Company 4.1 Global Immuno-oncology Drugs Market Size by Company 4.1.1 Top Global Immuno-oncology Drugs Manufacturers Ranked by Revenue (2021) 4.1.2 Global Immuno-oncology Drugs Revenue by Manufacturer (2017-2022) 4.1.3 Global Immuno-oncology Drugs Sales by Manufacturer (2017-2022) 4.1.4 Global Immuno-oncology Drugs Price by Manufacturer (2017-2022) 4.2 Global Immuno-oncology Drugs Concentration Ratio (CR) 4.2.1 Immuno-oncology Drugs Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Immuno-oncology Drugs in 2021 4.2.3 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Immuno-oncology Drugs Manufacturing Base Distribution, Product Type 4.3.1 Global Immuno-oncology Drugs Manufacturers, Headquarters and Distribution of Producing Region 4.3.2 Manufacturers Immuno-oncology Drugs Product Type 4.3.3 Date of International Manufacturers Enter into Immuno-oncology Drugs Market 4.4 Manufacturers Mergers & Acquisitions, Expansion Plans 4.5 United States Immuno-oncology Drugs Market Size by Company 4.5.1 Top Immuno-oncology Drugs Players in United States, Ranked by Revenue (2021) 4.5.2 United States Immuno-oncology Drugs Revenue by Players (2020, 2021 & 2022) 4.5.3 United States Immuno-oncology Drugs Sales by Players (2020, 2021 & 2022) 5 Global Immuno-oncology Drugs Market Size by Region 5.1 Global Immuno-oncology Drugs Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Immuno-oncology Drugs Market Size in Volume by Region (2017-2028) 5.2.1 Global Immuno-oncology Drugs Sales in Volume by Region: 2017-2022 5.2.2 Global Immuno-oncology Drugs Sales in Volume Forecast by Region (2023-2028) 5.3 Global Immuno-oncology Drugs Market Size in Value by Region (2017-2028) 5.3.1 Global Immuno-oncology Drugs Sales in Value by Region: 2017-2022 5.3.2 Global Immuno-oncology Drugs Sales in Value by Region: 2023-2028 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Immuno-oncology Drugs Market Size YoY Growth 2017-2028 6.1.2 North America Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Immuno-oncology Drugs Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Immuno-oncology Drugs Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Immuno-oncology Drugs Market Size YoY Growth 2017-2028 6.3.2 Europe Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Immuno-oncology Drugs Market Size YoY Growth 2017-2028 6.4.2 Latin America Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Immuno-oncology Drugs Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Immuno-oncology Drugs Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Amgen, Inc 7.1.1 Amgen, Inc Corporation Information 7.1.2 Amgen, Inc Description and Business Overview 7.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered 7.1.5 Amgen, Inc Recent Development 7.2 AstraZeneca, Plc 7.2.1 AstraZeneca, Plc Corporation Information 7.2.2 AstraZeneca, Plc Description and Business Overview 7.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products Offered 7.2.5 AstraZeneca, Plc Recent Development 7.3 Bristol-Myers Squibb 7.3.1 Bristol-Myers Squibb Corporation Information 7.3.2 Bristol-Myers Squibb Description and Business Overview 7.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products Offered 7.3.5 Bristol-Myers Squibb Recent Development 7.4 Celgene Corporation 7.4.1 Celgene Corporation Corporation Information 7.4.2 Celgene Corporation Description and Business Overview 7.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.4.4 Celgene Corporation Immuno-oncology Drugs Products Offered 7.4.5 Celgene Corporation Recent Development 7.5 Eli Lilly and Company 7.5.1 Eli Lilly and Company Corporation Information 7.5.2 Eli Lilly and Company Description and Business Overview 7.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.5.4 Eli Lilly and Company Immuno-oncology Drugs Products Offered 7.5.5 Eli Lilly and Company Recent Development 7.6 Merck & Co. 7.6.1 Merck & Co. Corporation Information 7.6.2 Merck & Co. Description and Business Overview 7.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.6.4 Merck & Co. Immuno-oncology Drugs Products Offered 7.6.5 Merck & Co. Recent Development 7.7 Hoffmann-La Roche AG 7.7.1 Hoffmann-La Roche AG Corporation Information 7.7.2 Hoffmann-La Roche AG Description and Business Overview 7.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Products Offered 7.7.5 Hoffmann-La Roche AG Recent Development 7.8 Johnson & Johnson 7.8.1 Johnson & Johnson Corporation Information 7.8.2 Johnson & Johnson Description and Business Overview 7.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.8.4 Johnson & Johnson Immuno-oncology Drugs Products Offered 7.8.5 Johnson & Johnson Recent Development 7.9 Novartis International AG 7.9.1 Novartis International AG Corporation Information 7.9.2 Novartis International AG Description and Business Overview 7.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.9.4 Novartis International AG Immuno-oncology Drugs Products Offered 7.9.5 Novartis International AG Recent Development 7.10 AbbVie, Inc. 7.10.1 AbbVie, Inc. Corporation Information 7.10.2 AbbVie, Inc. Description and Business Overview 7.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.10.4 AbbVie, Inc. Immuno-oncology Drugs Products Offered 7.10.5 AbbVie, Inc. Recent Development 7.11 Pfizer Inc. 7.11.1 Pfizer Inc. Corporation Information 7.11.2 Pfizer Inc. Description and Business Overview 7.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.11.4 Pfizer Inc. Immuno-oncology Drugs Products Offered 7.11.5 Pfizer Inc. Recent Development 7.12 Sanofi S.A. 7.12.1 Sanofi S.A. Corporation Information 7.12.2 Sanofi S.A. Description and Business Overview 7.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.12.4 Sanofi S.A. Products Offered 7.12.5 Sanofi S.A. Recent Development 7.13 EMD Serono, Inc. 7.13.1 EMD Serono, Inc. Corporation Information 7.13.2 EMD Serono, Inc. Description and Business Overview 7.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.13.4 EMD Serono, Inc. Products Offered 7.13.5 EMD Serono, Inc. Recent Development 7.14 Gilead Sciences Inc. 7.14.1 Gilead Sciences Inc. Corporation Information 7.14.2 Gilead Sciences Inc. Description and Business Overview 7.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.14.4 Gilead Sciences Inc. Products Offered 7.14.5 Gilead Sciences Inc. Recent Development 7.15 Prometheus Therapeutics & Diagnostics 7.15.1 Prometheus Therapeutics & Diagnostics Corporation Information 7.15.2 Prometheus Therapeutics & Diagnostics Description and Business Overview 7.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.15.4 Prometheus Therapeutics & Diagnostics Products Offered 7.15.5 Prometheus Therapeutics & Diagnostics Recent Development 7.16 Aduro BioTech 7.16.1 Aduro BioTech Corporation Information 7.16.2 Aduro BioTech Description and Business Overview 7.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.16.4 Aduro BioTech Products Offered 7.16.5 Aduro BioTech Recent Development 7.17 Galena Biopharma 7.17.1 Galena Biopharma Corporation Information 7.17.2 Galena Biopharma Description and Business Overview 7.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.17.4 Galena Biopharma Products Offered 7.17.5 Galena Biopharma Recent Development 7.18 Bavarian Nordic 7.18.1 Bavarian Nordic Corporation Information 7.18.2 Bavarian Nordic Description and Business Overview 7.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.18.4 Bavarian Nordic Products Offered 7.18.5 Bavarian Nordic Recent Development 7.19 Celldex Therapeutics 7.19.1 Celldex Therapeutics Corporation Information 7.19.2 Celldex Therapeutics Description and Business Overview 7.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.19.4 Celldex Therapeutics Products Offered 7.19.5 Celldex Therapeutics Recent Development 7.20 ImmunoCellular Therapeutics 7.20.1 ImmunoCellular Therapeutics Corporation Information 7.20.2 ImmunoCellular Therapeutics Description and Business Overview 7.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.20.4 ImmunoCellular Therapeutics Products Offered 7.20.5 ImmunoCellular Therapeutics Recent Development 7.21 Incyte 7.21.1 Incyte Corporation Information 7.21.2 Incyte Description and Business Overview 7.21.3 Incyte Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.21.4 Incyte Products Offered 7.21.5 Incyte Recent Development 7.22 Dendreon Corporation 7.22.1 Dendreon Corporation Corporation Information 7.22.2 Dendreon Corporation Description and Business Overview 7.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.22.4 Dendreon Corporation Products Offered 7.22.5 Dendreon Corporation Recent Development 7.23 Agilent Technologies Inc. 7.23.1 Agilent Technologies Inc. Corporation Information 7.23.2 Agilent Technologies Inc. Description and Business Overview 7.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.23.4 Agilent Technologies Inc. Products Offered 7.23.5 Agilent Technologies Inc. Recent Development 7.24 Agenus Inc. 7.24.1 Agenus Inc. Corporation Information 7.24.2 Agenus Inc. Description and Business Overview 7.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.24.4 Agenus Inc. Products Offered 7.24.5 Agenus Inc. Recent Development 7.25 Enzo Biochem, Inc. 7.25.1 Enzo Biochem, Inc. Corporation Information 7.25.2 Enzo Biochem, Inc. Description and Business Overview 7.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.25.4 Enzo Biochem, Inc. Products Offered 7.25.5 Enzo Biochem, Inc. Recent Development 7.26 Lonza Group 7.26.1 Lonza Group Corporation Information 7.26.2 Lonza Group Description and Business Overview 7.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.26.4 Lonza Group Products Offered 7.26.5 Lonza Group Recent Development 7.27 Bio-Rad Laboratories, Inc. 7.27.1 Bio-Rad Laboratories, Inc. Corporation Information 7.27.2 Bio-Rad Laboratories, Inc. Description and Business Overview 7.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.27.4 Bio-Rad Laboratories, Inc. Products Offered 7.27.5 Bio-Rad Laboratories, Inc. Recent Development 7.28 Avantor, Inc. 7.28.1 Avantor, Inc. Corporation Information 7.28.2 Avantor, Inc. Description and Business Overview 7.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.28.4 Avantor, Inc. Products Offered 7.28.5 Avantor, Inc. Recent Development 7.29 Spring Bank Pharmaceuticals, Inc. 7.29.1 Spring Bank Pharmaceuticals, Inc. Corporation Information 7.29.2 Spring Bank Pharmaceuticals, Inc. Description and Business Overview 7.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.29.4 Spring Bank Pharmaceuticals, Inc. Products Offered 7.29.5 Spring Bank Pharmaceuticals, Inc. Recent Development 7.30 Ferring Pharmaceuticals 7.30.1 Ferring Pharmaceuticals Corporation Information 7.30.2 Ferring Pharmaceuticals Description and Business Overview 7.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue and Gross Margin (2017-2022) 7.30.4 Ferring Pharmaceuticals Products Offered 7.30.5 Ferring Pharmaceuticals Recent Development 8 Industry Chain and Sales Channels Analysis 8.1 Immuno-oncology Drugs Industry Chain Analysis 8.2 Immuno-oncology Drugs Key Raw Materials 8.2.1 Key Raw Materials 8.2.2 Immuno-oncology Drugs Distributors 8.3 Immuno-oncology Drugs Production Mode & Process 8.4 Immuno-oncology Drugs Sales and Marketing 8.4.1 Immuno-oncology Drugs Sales Channels 8.4.2 Immuno-oncology Drugs Distributors 8.5 Immuno-oncology Drugs Customers 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
List of Tables Table 1. Immuno-oncology Drugs CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028 Table 2. Immuno-oncology Drugs Market Trends Table 3. Immuno-oncology Drugs Market Drivers Table 4. Immuno-oncology Drugs Market Challenges Table 5. Immuno-oncology Drugs Market Restraints Table 6. Global Immuno-oncology Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Immuno-oncology Drugs Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Immuno-oncology Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Immuno-oncology Drugs Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Immuno-oncology Drugs Manufacturers in Global Market, Ranking by Revenue (2021) Table 11. Global Immuno-oncology Drugs Revenue by Manufacturer, (US$ Million), 2017-2022 Table 12. Global Immuno-oncology Drugs Revenue Share by Manufacturer, 2017-2022 Table 13. Global Immuno-oncology Drugs Sales by Manufacturer, (K Units), 2017-2022 Table 14. Global Immuno-oncology Drugs Sales Share by Manufacturer, 2017-2022 Table 15. Global Immuno-oncology Drugs Price by Manufacturer (2017-2022) & (USD/Unit) Table 16. Global Immuno-oncology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) Table 17. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2021) Table 18. Top Players of Immuno-oncology Drugs in Global Market, Headquarters and Distribution of Producing Region Table 19. Manufacturers Immuno-oncology Drugs Product Type Table 20. Date of International Manufacturers Enter into Immuno-oncology Drugs Market Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans Table 22. Top Immuno-oncology Drugs Players in United States Market, Ranking by Revenue (2021) Table 23. United States Immuno-oncology Drugs Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 24. United States Immuno-oncology Drugs Revenue Share by Players, 2020, 2021 & 2022 Table 25. United States Immuno-oncology Drugs Sales by Players, (K Units), 2020, 2021 & 2022 Table 26. United States Immuno-oncology Drugs Sales Share by Players, 2020, 2021 & 2022 Table 27. Global Immuno-oncology Drugs Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 28. Global Immuno-oncology Drugs Sales in Volume by Region (2017-2022) & (K Units) Table 29. Global Immuno-oncology Drugs Sales in Volume Forecast by Region (2023-2028) & (K Units) Table 30. Global Immuno-oncology Drugs Sales in Value by Region (2017-2022) & (US$ Million) Table 31. Global Immuno-oncology Drugs Sales in Value Forecast by Region (2023-2028) & (US$ Million) Table 32. North America Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units) Table 33. North America Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 34. Asia Pacific Immuno-oncology Drugs Sales in Volume by Region (2017-2028) & (K Units) Table 35. Asia Pacific Immuno-oncology Drugs Sales in Value by Region (2017-2028) & (US$ Million) Table 36. Europe Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units) Table 37. Europe Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 38. Latin America Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units) Table 39. Latin Americaa Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 40. Middle East and Africa Immuno-oncology Drugs Sales in Volume by Country (2017-2028) & (K Units) Table 41. Middle East and Africa Immuno-oncology Drugs Sales in Value by Country (2017-2028) & (US$ Million) Table 42. Amgen, Inc Corporation Information Table 43. Amgen, Inc Description and Business Overview Table 44. Amgen, Inc Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 45. Amgen, Inc Immuno-oncology Drugs Product Table 46. Amgen, Inc Recent Development Table 47. AstraZeneca, Plc Corporation Information Table 48. AstraZeneca, Plc Description and Business Overview Table 49. AstraZeneca, Plc Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 50. AstraZeneca, Plc Product Table 51. AstraZeneca, Plc Recent Development Table 52. Bristol-Myers Squibb Corporation Information Table 53. Bristol-Myers Squibb Description and Business Overview Table 54. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 55. Bristol-Myers Squibb Product Table 56. Bristol-Myers Squibb Recent Development Table 57. Celgene Corporation Corporation Information Table 58. Celgene Corporation Description and Business Overview Table 59. Celgene Corporation Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 60. Celgene Corporation Product Table 61. Celgene Corporation Recent Development Table 62. Eli Lilly and Company Corporation Information Table 63. Eli Lilly and Company Description and Business Overview Table 64. Eli Lilly and Company Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 65. Eli Lilly and Company Product Table 66. Eli Lilly and Company Recent Development Table 67. Merck & Co. Corporation Information Table 68. Merck & Co. Description and Business Overview Table 69. Merck & Co. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 70. Merck & Co. Product Table 71. Merck & Co. Recent Development Table 72. Hoffmann-La Roche AG Corporation Information Table 73. Hoffmann-La Roche AG Description and Business Overview Table 74. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 75. Hoffmann-La Roche AG Product Table 76. Hoffmann-La Roche AG Recent Development Table 77. Johnson & Johnson Corporation Information Table 78. Johnson & Johnson Description and Business Overview Table 79. Johnson & Johnson Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 80. Johnson & Johnson Product Table 81. Johnson & Johnson Recent Development Table 82. Novartis International AG Corporation Information Table 83. Novartis International AG Description and Business Overview Table 84. Novartis International AG Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 85. Novartis International AG Product Table 86. Novartis International AG Recent Development Table 87. AbbVie, Inc. Corporation Information Table 88. AbbVie, Inc. Description and Business Overview Table 89. AbbVie, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 90. AbbVie, Inc. Product Table 91. AbbVie, Inc. Recent Development Table 92. Pfizer Inc. Corporation Information Table 93. Pfizer Inc. Description and Business Overview Table 94. Pfizer Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 95. Pfizer Inc. Product Table 96. Pfizer Inc. Recent Development Table 97. Sanofi S.A. Corporation Information Table 98. Sanofi S.A. Description and Business Overview Table 99. Sanofi S.A. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 100. Sanofi S.A. Product Table 101. Sanofi S.A. Recent Development Table 102. EMD Serono, Inc. Corporation Information Table 103. EMD Serono, Inc. Description and Business Overview Table 104. EMD Serono, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 105. EMD Serono, Inc. Product Table 106. EMD Serono, Inc. Recent Development Table 107. Gilead Sciences Inc. Corporation Information Table 108. Gilead Sciences Inc. Description and Business Overview Table 109. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 110. Gilead Sciences Inc. Product Table 111. Gilead Sciences Inc. Recent Development Table 112. Prometheus Therapeutics & Diagnostics Corporation Information Table 113. Prometheus Therapeutics & Diagnostics Description and Business Overview Table 114. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 115. Prometheus Therapeutics & Diagnostics Product Table 116. Prometheus Therapeutics & Diagnostics Recent Development Table 117. Aduro BioTech Corporation Information Table 118. Aduro BioTech Description and Business Overview Table 119. Aduro BioTech Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 120. Aduro BioTech Product Table 121. Aduro BioTech Recent Development Table 122. Galena Biopharma Corporation Information Table 123. Galena Biopharma Description and Business Overview Table 124. Galena Biopharma Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 125. Galena Biopharma Product Table 126. Galena Biopharma Recent Development Table 127. Bavarian Nordic Corporation Information Table 128. Bavarian Nordic Description and Business Overview Table 129. Bavarian Nordic Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 130. Bavarian Nordic Product Table 131. Bavarian Nordic Recent Development Table 132. Celldex Therapeutics Corporation Information Table 133. Celldex Therapeutics Description and Business Overview Table 134. Celldex Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 135. Celldex Therapeutics Product Table 136. Celldex Therapeutics Recent Development Table 137. ImmunoCellular Therapeutics Corporation Information Table 138. ImmunoCellular Therapeutics Description and Business Overview Table 139. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 140. ImmunoCellular Therapeutics Product Table 141. ImmunoCellular Therapeutics Recent Development Table 142. Incyte Corporation Information Table 143. Incyte Description and Business Overview Table 144. Incyte Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 145. Incyte Product Table 146. Incyte Recent Development Table 147. Dendreon Corporation Corporation Information Table 148. Dendreon Corporation Description and Business Overview Table 149. Dendreon Corporation Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 150. Dendreon Corporation Product Table 151. Dendreon Corporation Recent Development Table 152. Agilent Technologies Inc. Corporation Information Table 153. Agilent Technologies Inc. Description and Business Overview Table 154. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 155. Agilent Technologies Inc. Product Table 156. Agilent Technologies Inc. Recent Development Table 157. Agenus Inc. Corporation Information Table 158. Agenus Inc. Description and Business Overview Table 159. Agenus Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 160. Agenus Inc. Product Table 161. Agenus Inc. Recent Development Table 162. Enzo Biochem, Inc. Corporation Information Table 163. Enzo Biochem, Inc. Description and Business Overview Table 164. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 165. Enzo Biochem, Inc. Product Table 166. Enzo Biochem, Inc. Recent Development Table 167. Lonza Group Corporation Information Table 168. Lonza Group Description and Business Overview Table 169. Lonza Group Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 170. Lonza Group Product Table 171. Lonza Group Recent Development Table 172. Bio-Rad Laboratories, Inc. Corporation Information Table 173. Bio-Rad Laboratories, Inc. Description and Business Overview Table 174. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 175. Bio-Rad Laboratories, Inc. Product Table 176. Bio-Rad Laboratories, Inc. Recent Development Table 177. Avantor, Inc. Corporation Information Table 178. Avantor, Inc. Description and Business Overview Table 179. Avantor, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 180. Avantor, Inc. Product Table 181. Avantor, Inc. Recent Development Table 182. Spring Bank Pharmaceuticals, Inc. Corporation Information Table 183. Spring Bank Pharmaceuticals, Inc. Description and Business Overview Table 184. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 185. Spring Bank Pharmaceuticals, Inc. Product Table 186. Spring Bank Pharmaceuticals, Inc. Recent Development Table 187. Ferring Pharmaceuticals Corporation Information Table 188. Ferring Pharmaceuticals Description and Business Overview Table 189. Ferring Pharmaceuticals Immuno-oncology Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022) Table 190. Ferring Pharmaceuticals Product Table 191. Ferring Pharmaceuticals Recent Development Table 192. Key Raw Materials Lists Table 193. Raw Materials Key Suppliers Lists Table 194. Immuno-oncology Drugs Customers List Table 195. Immuno-oncology Drugs Distributors List Table 196. Research Programs/Design for This Report Table 197. Key Data Information from Secondary Sources Table 198. Key Data Information from Primary Sources List of Figures Figure 1. Immuno-oncology Drugs Product Picture Figure 2. Global Immuno-oncology Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Immuno-oncology Drugs Market Size 2017-2028 (US$ Million) Figure 4. Global Immuno-oncology Drugs Sales 2017-2028 (K Units) Figure 5. United States Immuno-oncology Drugs Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 6. United States Immuno-oncology Drugs Market Size 2017-2028 (US$ Million) Figure 7. United States Immuno-oncology Drugs Sales 2017-2028 (K Units) Figure 8. United States Immuno-oncology Drugs Market Share in Global, in Value (US$ Million) 2017-2028 Figure 9. United States Immuno-oncology Drugs Market Share in Global, in Volume (K Units) 2017-2028 Figure 10. Immuno-oncology Drugs Report Years Considered Figure 11. Product Picture of Immune Checkpoint Inhibitors Figure 12. Product Picture of Immune System Modulators Figure 13. Product Picture of Cancer Vaccines Figure 14. Product Picture of Oncolytic Virus Figure 15. Product Picture of Others Figure 16. Global Immuno-oncology Drugs Market Share by Type in 2022 & 2028 Figure 17. Global Immuno-oncology Drugs Sales in Value by Type (2017-2028) & (US$ Million) Figure 18. Global Immuno-oncology Drugs Sales Market Share in Value by Type (2017-2028) Figure 19. Global Immuno-oncology Drugs Sales by Type (2017-2028) & (K Units) Figure 20. Global Immuno-oncology Drugs Sales Market Share in Volume by Type (2017-2028) Figure 21. Global Immuno-oncology Drugs Price by Type (2017-2028) & (USD/Unit) Figure 22. United States Immuno-oncology Drugs Market Share by Type in 2022 & 2028 Figure 23. United States Immuno-oncology Drugs Sales in Value by Type (2017-2028) & (US$ Million) Figure 24. United States Immuno-oncology Drugs Sales Market Share in Value by Type (2017-2028) Figure 25. United States Immuno-oncology Drugs Sales by Type (2017-2028) & (K Units) Figure 26. United States Immuno-oncology Drugs Sales Market Share in Volume by Type (2017-2028) Figure 27. United States Immuno-oncology Drugs Price by Type (2017-2028) & (USD/Unit) Figure 28. Product Picture of Hospitals Figure 29. Product Picture of Clinics Figure 30. Product Picture of Ambulatory Surgical Centers Figure 31. Global Immuno-oncology Drugs Market Share by Application in 2022 & 2028 Figure 32. Global Immuno-oncology Drugs Sales in Value by Application (2017-2028) & (US$ Million) Figure 33. Global Immuno-oncology Drugs Sales Market Share in Value by Application (2017-2028) Figure 34. Global Immuno-oncology Drugs Sales by Application (2017-2028) & (K Units) Figure 35. Global Immuno-oncology Drugs Sales Market Share in Volume by Application (2017-2028) Figure 36. Global Immuno-oncology Drugs Price by Application (2017-2028) & (USD/Unit) Figure 37. United States Immuno-oncology Drugs Market Share by Application in 2022 & 2028 Figure 38. United States Immuno-oncology Drugs Sales in Value by Application (2017-2028) & (US$ Million) Figure 39. United States Immuno-oncology Drugs Sales Market Share in Value by Application (2017-2028) Figure 40. United States Immuno-oncology Drugs Sales by Application (2017-2028) & (K Units) Figure 41. United States Immuno-oncology Drugs Sales Market Share in Volume by Application (2017-2028) Figure 42. United States Immuno-oncology Drugs Price by Application (2017-2028) & (USD/Unit) Figure 43. North America Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units) Figure 44. North America Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 45. U.S. Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 46. Canada Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 47. Europe Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units) Figure 48. Europe Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 49. Germany Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 50. France Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 51. U.K. Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 52. Italy Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 53. Russia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 54. Asia-Pacific Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units) Figure 55. Asia-Pacific Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 56. China Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 57. Japan Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 58. South Korea Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 59. India Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 60. Australia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 61. Taiwan Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 62. Indonesia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 63. Thailand Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 64. Malaysia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 65. Philippines Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 66. Latin America Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units) Figure 67. Latin America Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 68. Mexico Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 69. Brazil Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 70. Argentina Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 71. Middle East & Africa Immuno-oncology Drugs Sales in Volume Growth Rate 2017-2028 (K Units) Figure 72. Middle East & Africa Immuno-oncology Drugs Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 73. Turkey Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 74. Saudi Arabia Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 75. U.A.E Immuno-oncology Drugs Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 76. Immuno-oncology Drugs Value Chain Figure 77. Immuno-oncology Drugs Production Process Figure 78. Channels of Distribution Figure 79. Distributors Profiles Figure 80. Bottom-up and Top-down Approaches for This Report Figure 81. Data Triangulation Figure 82. Key Executives Interviewed
Amgen, Inc AstraZeneca, Plc Bristol-Myers Squibb Celgene Corporation Eli Lilly and Company Merck & Co. Hoffmann-La Roche AG Johnson & Johnson Novartis International AG AbbVie, Inc. Pfizer Inc. Sanofi S.A. EMD Serono, Inc. Gilead Sciences Inc. Prometheus Therapeutics & Diagnostics Aduro BioTech Galena Biopharma Bavarian Nordic Celldex Therapeutics ImmunoCellular Therapeutics Incyte Dendreon Corporation Agilent Technologies Inc. Agenus Inc. Enzo Biochem, Inc. Lonza Group Bio-Rad Laboratories, Inc. Avantor, Inc. Spring Bank Pharmaceuticals, Inc. Ferring Pharmaceuticals
Injection Molding Materials market is segmented by region (country), players, by Type and by Appl ... Read More
In-mold Label market is segmented by region (country), players, by Type and by Application. Playe ... Read More
Lighting Fixture market is segmented by region (country), players, by Type and by Application. Pl ... Read More
Lip Care Products Packaging market is segmented by region (country), players, by Type and by Appl ... Read More